Evidence map›Paper›PMID 41758056›Full record

ReviewHepatology communications2026

Mitochondrial targets in IDH1-mutated cholangiocarcinoma.

Camila Carvalho, Fulei Wuchu, Nicole Peterson, Deepak Nagrath, Arathi Mohan, Vaibhav Sahai

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Hepatology communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Camila CarvalhoDivision of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.ORCID 0000-0003-4675-3369
Fulei WuchuDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan, USA.
Nicole PetersonDivision of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Deepak NagrathDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan, USA.
Arathi MohanDivision of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.ORCID 0000-0001-9024-6589
Vaibhav SahaiDivision of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.ORCID 0000-0003-1892-1548

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cholangiocarcinoma (CCA), a subset of biliary tract cancers, remains a therapeutically challenging malignancy with poor long-term survival despite recent advances in targeted therapies. Recent data suggest that IDH1-mutated CCA exhibits unique mitochondrial vulnerabilities. In this report, we discuss the emerging role of mitochondrial metabolism as a target in IDH1-mutated CCA, including preclinical evidence supporting the inhibition of the tricarboxylic acid (TCA) cycle, glutamine metabolism, and potential combination approaches. We aim to highlight the growing need to integrate mitochondrial-targeted strategies into future clinical investigations.

Indexed as

Bile Duct NeoplasmsCholangiocarcinomaIsocitrate DehydrogenaseMitochondriaAnimalsCitric Acid CycleGlutamineHumansMolecular Targeted TherapyMutationGlutamineIDH1 protein, humanIsocitrate Dehydrogenasecholangiocarcinomaivosidenibmutant isocitrate dehydrogenasetargeted therapy

Identifiers

PMID41758056
PMCPMC12947996

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.